Werewolf Therapeutics (HOWL) finance VP reports stock and option holdings on Form 3

Rhea-AI Filing Summary

Werewolf Therapeutics, Inc. VP of Finance & Corporate Controller Michael J. Urban filed an initial Form 3 showing his equity holdings. He directly holds stock options covering 52,500 shares at an exercise price of $3.6500, 29,365 shares at $4.6400, 10,000 shares at $1.5700, and 54,800 shares at $1.5600, with expiration dates ranging from 2033 to 2035. He also directly owns 5,284 shares of Werewolf Therapeutics common stock.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Urban Michael J.

(Last) (First) (Middle)

C/O WEREWOLF THERAPEUTICS, INC.

200 TALCOTT AVENUE, 2ND FLOOR

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/13/2026

3. Issuer Name and Ticker or Trading Symbol
Werewolf Therapeutics, Inc. [ HOWL ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP of Finance & Corp. Contr.

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	5,284	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	05/31/2033	Common Stock	52,500	$3.65	D
Stock Option (right to buy)	(2)	01/01/2034	Common Stock	29,365	$4.64	D
Stock Option (right to buy)	(3)	12/18/2034	Common Stock	10,000	$1.57	D
Stock Option (right to buy)	(4)	01/01/2035	Common Stock	54,800	$1.56	D

Explanation of Responses:

1. The option was granted on June 1, 2023. The shares underlying the option vested as to 25% on May 15, 2024, and the remainder vest in substantially equal monthly installments thereafter through May 15, 2027.

2. The option was granted on January 2, 2024 with a Vesting Commencement Date of January 1, 2024. The shares underlying the option vest in substantially equal monthly installments over four years, commencing on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2028.

3. The option was granted on December 19, 2024, and is fully vested.

4. The option was granted on January 2, 2025 with a Vesting Commencement Date of January 1, 2025. The shares underlying the option vest in substantially equal monthly installments over four years, commencing on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2029.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

	/s/ Jonathan Owen, Attorney-in-fact	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the HOWL Form 3 filing by Michael J. Urban show?

The Form 3 shows VP of Finance & Corporate Controller Michael J. Urban’s initial ownership in Werewolf Therapeutics, Inc., including multiple option grants and common stock, as he becomes a reporting insider under SEC rules.

How many Werewolf Therapeutics (HOWL) stock options does Michael J. Urban hold?

Michael J. Urban holds several stock option positions on Werewolf Therapeutics common stock: 52,500 shares at $3.6500, 29,365 at $4.6400, 10,000 at $1.5700, and 54,800 at $1.5600, all held directly with expirations between 2033 and 2035.

What common stock holdings of Werewolf Therapeutics (HOWL) are reported on this Form 3?

The Form 3 reports that Michael J. Urban directly owns 5,284 shares of Werewolf Therapeutics common stock. This is separate from his stock option holdings and represents current issued and outstanding shares held in his name.

Are the stock options in the HOWL Form 3 already vested?

Some options are fully vested while others vest over time. Footnotes state one grant is fully vested, while others vest 25% initially or in substantially equal monthly installments through dates ranging from May 15, 2027 to January 1, 2029.

What are the expiration dates of Michael J. Urban’s HOWL stock options?

The reported stock options on Werewolf Therapeutics common stock expire on dates between May 31, 2033 and January 1, 2035. Each option series has its own specific expiration date tied to the original grant terms.

Does the HOWL Form 3 indicate any recent insider buying or selling?

No buy or sell transactions are indicated. The entries are classified as holdings with unknown transaction codes, reflecting Mr. Urban’s existing positions rather than new market purchases or sales of Werewolf Therapeutics securities.